ClinicalTrials.gg
CompletedNCT05567510Updated Feb 17, 2023

A Study to Evaluate the Metabolism and Excretion of BMS-986369 in Healthy Male Participants

A Phase 1 interventional study of BMS-986369 in Healthy Participants, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-02-17.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2022, 3 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The purpose of the study is to assess mass balance, biotransformation, and excretion of BMS-986369 following study drug administration.

02

Conditions studied

  • Healthy Participants

Keywords

  • BMS-986369
  • Drug absorption, distribution, metabolism, and excretion (ADME)
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male participants, of any race, determined by the investigator to have no significant deviation from normal in medical history or physical examination, which correspond to a condition that could potentially increase the risk for the participants, or jeopardize the integrity of the study data in 12-lead measurements, vital signs, and clinical laboratory determinations at screening and/or check-in.
  • (BMI) of 18.0 through 33.0 kilogram meter squared (kg/m\^2), inclusive. BMI = weight kg/height m\^2.
  • must be greater than 2,500 per microliter (μL) at screening and Day -1.

Exclusion criteria

Exclusion Criteria:

  • Any significant acute or chronic medical illness that presents a potential risk to the participant in the opinion of the investigator and/or may compromise the objectives of the study.
  • Current or recent (within 3 months of study intervention administration) history of endocrine, GI, cardiovascular, peripheral vascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities/diseases.
  • Participant has any surgical or medical conditions possibly affecting drug absorption, distribution, metabolism, and excretion (ADME) (eg, bariatric procedure). Appendectomy, cholecystectomy, and uncomplicated hernia repair are acceptable. Prior procedures of unclear ADME significance should be reviewed with the Sponsor's Medical Monitor.

Prior/Concomitant Therapy

  • Participant has participated in another trial within 4 weeks prior to screening. For participants who have participated in an investigational trial where no trial drug was administered or invasive procedure performed, the waiting interval may be eliminated.
  • Participant has received a vaccination, including coronavirus disease 2019 (COVID-19) vaccine, within 30 days prior to the IP dose or plans to receive vaccination within 2 months after dosing.
  • Participant has used a prescribed systemic or topical medication (eg, analgesics, anesthetics, anti-coagulants, etc.) within 30 days prior to the first dose administration. Exceptions may be made on a case-by-case basis if considered not to interfere with study objectives as agreed to by the investigator and Sponsor's Medical Monitor.
  • Use of inducers (eg, St. John's wort) and inhibitors (eg, grapefruit juice) within 30 days prior to dosing.
  • Participant has used any non-prescribed systemic or topical medications (for example, vitamin/mineral supplements, and herbal medicines) within 14 days prior to the first dose administration. Exceptions may be made on a case-by-case basis if considered not to interfere with study objectives as agreed to by the investigator and Sponsor's Medical Monitor (eg, occasional use of acetaminophen).
  • Participant has received immunization with a live or within 2 months prior to dosing or is planning to receive immunization with a live or non-live vaccine for 2 months following dosing.
  • Participated in a radiolabeled drug study, where exposures are known to the investigator, within the previous 4 months prior to check-in (Day -1); or participated in a radiolabeled drug study, where exposures are not known to the investigator, within the previous 6 months prior to check-in (Day -1). The total 12-month exposure from this study and a maximum of 2 other previous studies within 4 to 12 months of this study will be within the CFR-recommended levels considered safe, per US Title 21 CFR 361.15: less than 5,000 mrem whole body annual exposure, with consideration given to the half-lives of the previous radiolabeled study drugs received.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    BMS-986369

    Drug: BMS-986369

Interventions

06

What researchers measure

Primary outcomes

  1. Total radioactivity recovered in whole blood

    Time frame: Up to 22 days

  2. Total radioactivity recovered in plasma

    Time frame: Up to 22 days

  3. Total radioactivity recovered in urine

    Time frame: Up to 22 days

  4. Total radioactivity recovered in feces

    Time frame: Up to 22 days

  5. Total radioactivity recovered in vomit

    Time frame: Up to 22 days

  6. Maximum observed plasma concentration (Cmax)

    Time frame: Up to 22 days

  7. Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUC[0-T])

    Time frame: Up to 22 days

  8. Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC[INF])

    Time frame: Up to 22 days

  9. Total radioactivity recovered in whole blood to plasma ratio

    Time frame: Up to 22 days

Secondary outcomes

  1. Number of participants with adverse events (AEs)

    Time frame: Up to 28 days

  2. Number of participants with serious adverse events (SAEs)

    Time frame: Up to 28 days

  3. Number of participants with vital sign abnormalities

    Time frame: Up to 28 days

  4. Number of participants with electrocardiogram (ECG) abnormalities

    Time frame: Up to 28 days

  5. Number of participants with clinical laboratory test abnormalities

    Time frame: Up to 28 days

  6. Number of participants with physical examination abnormalities

    Time frame: Up to 28 days

07

Study locations

1 site
  • Labcorp Clinical Research Unit - Madison
    Madison, Wisconsin 53704-2526, United States
08

References and documents

Individual participant data

Plan to share: No — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myers Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosurecommitment.html

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2022 to primary completion in Dec 2022, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2022
First posted
Oct 5, 2022
StartActual
Oct 20, 2022
Primary completionActual
Dec 27, 2022
CompletionActual
Dec 27, 2022
Last update
Feb 17, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05567510
Responsible party
Sponsor
First posted
Oct 5, 2022
Start date
Oct 20, 2022
Primary completion
Dec 27, 2022
Completion
Dec 27, 2022
Last update
Feb 17, 2023

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Golcadomide

Start the discussion